西黄胶囊联合多西他赛+顺铂二线化疗在晚期非小细胞肺癌患者中的应用效果

Application effect of Xihuang capsule combined with docetaxel+cisplatin second-line chemotherapy in patients with advanced non-small cell lung cancer

目的探讨西黄胶囊联合多西他赛+顺铂二线化疗在晚期非小细胞肺癌(NSCLC)患者中的应用效果。方法根据治疗方案的不同将86例晚期NSCLC患者分为对照组(42例)和观察组(44例),对照组患者接受多西他赛+顺铂二线化疗,观察组患者在对照组的基础上接受西黄胶囊治疗。比较两组患者的临床疗效、肿瘤标志物[癌胚抗原(CEA)、鳞状细胞癌抗原(SCC-Ag)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]、血管生长因子[碱性成纤维细胞生长因子(bFGF)、血管内皮生长因子(VEGF)]、生活质量[肺癌患者生活质量测定量表(FACT-L)]及不良反应发生情况。结果观察组患者的客观缓解率为63.64%,高于对照组患者的38.10%,差异有统计学意义(P﹤0.05)。治疗后,两组患者血清CEA、SCC-Ag、CYFRA21-1、bFGF、VEGF水平均低于本组治疗前,FACT-L评分均高于本组治疗前,观察组患者血清CEA、SCC-Ag、CYFRA21-1、bFGF、VEGF水平均低于对照组,FACT-L评分高于对照组,差异均有统计学意义(P﹤0.05)。观察组患者消化道不适、白细胞减少发生率均低于对照组,差异均有统计学意义(P﹤0.05)。结论西黄胶囊联合多西他赛+顺铂二线化疗应用于晚期NSCLC患者中的临床疗效较好,可以有效抑制血管生成,降低肿瘤标志物水平,提高生活质量,且安全性较高。

Objective To investigate the application effect of Xihuang capsule combined with docetaxel+cisplatin second-line chemotherapy in patients with advanced non-small cell lung cancer(NSCLC).Method According to the different treatment regimens,86 patients with advanced NSCLC were divided into control group(42 cases)and observation group(44 cases).The control group received docetaxel+cisplatin second-line chemotherapy,and the observation group received Xihuang capsule on the basis of the control group.The clinical efficacy,tumor markers[carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC-Ag),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)],angiogenesis factors[basic fibroblast growth factor(bFGF),vascular endothelial growth factor(VEGF)],quality of life[functional assessment of cancer therapy-lung(FACT-L)]and the occurrence of adverse reactions between the two groups were compared.Result The objective remission rate of observation group was 63.64%,which was higher than 38.10%of control group,and the difference was statistically significant(P<0.05).After treatment,serum CEA,SCC-Ag,CYFRA21-1,bFGF and VEGF levels in two groups were lower than those before treatment,FACT-L scores were higher than those before treatment,serum CEA,SCC-Ag,CYFRA21-1,bFGF and VEGF levels in observation group were lower than those in control group,FACT-L score was higher than that in control group,and the differences were statistically significant(P<0.05).The incidence of digestive tract discomfort and leukopenia in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).Conclusion Xihuang capsule combined with docetaxel+cisplatin second-line chemotherapy has good clinical efficacy in patients with advanced NSCLC,which can effectively inhibit angiogenesis,reduce the levels of tumor markers,and improve the quality of life,with high safety.